title: Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer.
abstract: OBJECTIVE
  To determine the biological characteristics of oropharyngeal squamous cell carcinoma (OpSCC) and related outcome.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  Patients (N=60) with primary OpSCC from 2000 to 2005 were retrospectively identified from Pathology database and the outcome was confirmed through chart review. Among these, 41 biopsy samples with enough tissues were retrieved to construct a tissue microarray for detection of the presence of high-risk human papillomavirus (HPV) using Chromogenic in situ hybridization (CISH) as well as the expression of p16 and cyclin D1 using immunohistochemistry.
  
  
  METHODS
  Disease-free survival.
  
  
  RESULTS
  Among 60 patients, 39 (65%) patients had no recurrence or died without disease at the last follow-up (disease-free survival or Group 1), and 21 (35%) patients had persistent disease or died of disease (progression-free survival or Group 2). Although follow-up time was twice as long in group 1 (4.7 ± 2.2 vs. 2.0 ± 1.6 years; P < 0.0001), there was no difference between the 2 groups in age, gender, smoking/alcohol habits, TNM staging and treatment modalities. Among those 41 cases with available tumour tissues, there was no difference in HPV status and p16 expression between the 2 groups but a significant difference in cyclin D1 expression (P = 0.05). Using Kaplan-Meir survival analysis and log-rank test, cyclin D1 overexpression was highly associated with a poor prognosis when comparing time to outcome (P < 0.0001).
  
  
  CONCLUSIONS
  Cyclin D1 overexpression is a potential prognostic marker of OpSCC.
authors.affiliation: Integrative Oncology, BC Cancer Agency & Research Centre, Vancouver, BC, Canada. CPoh@bccancer.bc.ca.
authors.forename: Rui Jun
authors.initials: RJ
authors.lastname: Lin
authors.forename: Tarinee
authors.initials: T
authors.lastname: Lubpairee
authors.forename: Kelly Y
authors.initials: KY
authors.lastname: Liu
authors.forename: Donald W
authors.initials: DW
authors.lastname: Anderson
authors.forename: Scott
authors.initials: S
authors.lastname: Durham
authors.forename: Catherine F
authors.initials: CF
authors.lastname: Poh
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000821:virology; D019938:Cyclin D1 / Q000378:metabolism*; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000821:virology; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization / Q000379:methods; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D009959:Oropharyngeal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000821:virology; D011379:Prognosis; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D046888:Tissue Array Analysis; D016896:Treatment Outcome
chemical_list: C530104:CCND1 protein, human; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D019938:Cyclin D1